Concepedia

Author

Conrad Jacobs

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

C Jacobs, C. Jacobs, Conrad Jacobs, Conrad R. Jacobs

11

Publications

2.1K

Citations

8

H-Index

26

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)The Medical Oncology Centre of RosebankUlsan CollegeThe Maria Sklodowska-Curie National Research Institute of OncologyYonsei University
CJ

About

Conrad Jacobs is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

1.9K

2

Health Sciences

3

3

545

3

Diagnostic Sciences

1

1

12

4

Gastroenterology

1

1

1.3K

5

Head And Neck Surgery

1

1

19

Conrad Jacobs

×

8

Publications

2.1K

Citations

8

H-Index

YearCitations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez,

The Lancet Oncology

2023

521

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

Fred Saad, Egils Vjaters, Neal D. Shore,

Journal of Clinical Oncology

2024

102

Lymphomas of the head and neck.

Anthony Po Wing Yuen, Conrad Jacobs

PubMed

1999

78

A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma

Mariko Mani, Rachna T. Shroff, Conrad Jacobs,

Journal of Clinical Oncology

2008

24

Use of methotrexate and 5-FU for recurrent head and neck cancer.

Conrad Jacobs

PubMed

1982

19

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.

Conrad Jacobs, Bernardo L. Rapoport, Sze Wai Chan,

Journal of Clinical Oncology

2021

12

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma

Conrad Jacobs, Bernardo L. Rapoport, Graham Cohen,

Cancer Research

2021

12

Page 1